| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/23/2023 | 110.08% | SVB Leerink | $42 → $10 | Maintains | Outperform |
| 10/14/2022 | 68.07% | Goldman Sachs | → $8 | Downgrades | Buy → Neutral |
| 10/14/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 10/13/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 09/23/2022 | 1601.68% | Goldman Sachs | $49 → $81 | Maintains | Buy |
| 09/06/2022 | 1160.5% | Guggenheim | $50 → $60 | Maintains | Buy |
| 05/09/2022 | 1244.54% | Oppenheimer | $75 → $64 | Maintains | Outperform |
| 03/24/2022 | 1013.45% | Goldman Sachs | $69 → $53 | Maintains | Buy |
| 12/20/2021 | 782.35% | SVB Leerink | $50 → $42 | Maintains | Outperform |
| 11/18/2021 | 950.42% | Mizuho | → $50 | Initiates Coverage On | → Buy |
| 10/28/2020 | 740.34% | Goldman Sachs | $69 → $40 | Downgrades | Buy → Neutral |
| 05/04/2020 | 1475.63% | SunTrust Robinson Humphrey | → $75 | Initiates Coverage On | → Buy |
| 04/21/2020 | 1223.53% | Goldman Sachs | → $63 | Initiates Coverage On | → Buy |
| 01/27/2020 | 1475.63% | Jefferies | → $75 | Initiates Coverage On | → Buy |
| 12/16/2019 | 1244.54% | Guggenheim | → $64 | Initiates Coverage On | → Buy |
What is the target price for Relmada Therapeutics (RLMD)?
The latest price target for Relmada Therapeutics (NASDAQ: RLMD) was reported by SVB Leerink on January 23, 2023. The analyst firm set a price target for $10.00 expecting RLMD to rise to within 12 months (a possible 110.08% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Relmada Therapeutics (RLMD)?
The latest analyst rating for Relmada Therapeutics (NASDAQ: RLMD) was provided by SVB Leerink, and Relmada Therapeutics maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Relmada Therapeutics (RLMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relmada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relmada Therapeutics was filed on January 23, 2023 so you should expect the next rating to be made available sometime around January 23, 2024.
Is the Analyst Rating Relmada Therapeutics (RLMD) correct?
While ratings are subjective and will change, the latest Relmada Therapeutics (RLMD) rating was a maintained with a price target of $42.00 to $10.00. The current price Relmada Therapeutics (RLMD) is trading at is $4.76, which is out of the analyst's predicted range.